MedTrace Logo

Cognitive Enhancement in Healthy Elderly People

NCT04997226 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2022-03-16

No results posted yet for this study

Summary

According to the European Commission Special Report, till 2030 it is expected ca. 40% increase of population aged 66-79. Increasing population of elderly people in modern society has suggested that more individuals are expected to suffer from cognitive deficits, as chronological aging is usually accompanied by declined cognition, in particular memory functions.

The cognitive decline reaches medical attention for about 5-25% of the elderly population (over 65 years of age) as they suffer from Mild Cognitive Impairment (MCI). MCI is usually referred to as an intermediate phase between the expected cognitive decline of normal aging and the pathological cognitive decline linked to dementia. In recent years, a new viewpoint argues that substantial improvement in cognitive function may be possible even in older age, using appropriately designed training programs. In the current project the investigators propose a potential intervention that might delay the onset of dementia by maintaining cognitive performance in general and improving in MCI in particular.

The current approach is to employ cognitive enhancement protocols, such as the combination of non-invasive, low intensity electrical stimulation and memory training aiming to preserve and ultimately improve cognitive abilities in MCI and healthy elderly.

Conditions

  • Transcranial Direct Current Stimulation
  • Transcranial Alternating Current Stimulation

Interventions

DEVICE

tDCS or tACS over the left DLPFC with adaptive memory game

This intervention is described in arms 1 and 3.

DEVICE

Sham tDCS or tACS over the left DLPFC with adaptive memory game

This intervention is described in arms 2 and 4.

Sponsors & Collaborators

  • Bar-Ilan University, Israel

    lead OTHER

Principal Investigators

  • Michal Lavidor, Prof. · Bar Ilan University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
FACTORIAL

Eligibility

Min Age
55 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-09-01
Primary Completion
2022-10-30
Completion
2023-10-30

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04997226 on ClinicalTrials.gov